Yıl: 2011 Cilt: 39 Sayı: 8 Sayfa Aralığı: 675 - 682 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi

Öz:
Amaç: Bu çalışmada, koroner arter hastalığı için uyguladığımız paklitaksel salınımlı stent (Genius TAXCOR I) işlemleri ve hastaların takip sonuçları değerlendirildi. Çalışma planı: Çalışmaya doğal koroner arterlerde saptanan yeni lezyona elektif olarak paklitaksel salınımlı stent yerleştirilen 101 hasta (75 erkek, 26 kadın; ort. yaş 60±10) alındı. On altı hastaya iki adet stent yerleştirildi. Lezyonların dağılımı tip A (%23.9), tip B1 (%29.1), tip B2 (%32.5) ve tip C (%14.5) şeklindeydi. On iki lezyonda (%10.3) hafif kıvrım, 32’sinde (%27.4) hafif kalsifikasyon, 12’sinde (%10.3) 45 dereceden fazla açılanma izlenirken, sekiz lezyonda (%7.7) trombüs vardı. Stent uygulamasından sonra hastalar 1, 6, 12. aylarda ve daha sonra yıllık olarak izlendi. Ortalama izlem süresi 48.9±5.7 ay (dağılım 35-60 ay) idi. Bulgular: Stent yerleştirme işlemi tüm hastalarda başarıyla gerçekleştirildi. Lezyonlarda ortalama darlık yüzdesi %82.8±9.9, ortalama stent çapı 3.1±0.6 mm, ortalama stent uzunluğu 16.0±5.2 mm idi. İzlem döneminde 46 hastada (%45.5) koroner anjiyografi gerekti. Bu hastaların sekizine (%17.4) hedef damar revaskülarizasyonu, dördüne (%8.7) hedef lezyon revaskülarizasyonu uygulandı. Bir hasta (%1.0) ani kardiyak ölüm nedeniyle kaybedildi. Sonuç: Göreceli olarak düşük-orta riskli bir hasta grubunu içeren bu çalışmanın klinik ve anjiyografik takip sonuçları, Genius TAXCOR I stentinin, stent trombozu ve tekrarlayan darlıkları önlemede etkili ve yararlı olduğunu göstermektedir.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi Ortopedi

A retrospective analysis of our paclitaxel-eluting stent (Genius TAXCOR I) implantations and follow-up results

Öz:
Objectives: We evaluated our paclitaxel-eluting stent (Genius TAXCOR I) implantations and follow-up results in patients with coronary artery disease. Study design: The study included 101 patients (75 men, 26 women; mean age 60±10 years) who underwent elective paclitaxel-eluting stent deployment for de novo native coronary artery lesions. Sixteen patients received two stents. Lesion types were as follows: type A (23.9%), type B1 (29.1%), type B2 (32.5%), and type C (14.5%). Twelve lesions (10.3%) exhibited mild tortuosity, 32 (27.4%) had mild calcification, 12 had (10.3%) an angulation of more than 45 degrees, while eight (7.7%) had thrombus. Following stent implantation, the patients were examined at 1, 6, and 12 months, and annually thereafter. The mean followup period was 48.9±5.7 months (range 35 to 60 months). Results: Stent implantation was successful in all the patients. The mean diameter stenosis was 82.8±9.9%, the mean stent diameter was 3.1±0.6 mm, and the mean stent length was 16.0±5.2 mm. During the follow-up period, 46 patients (45.5%) required coronary angiography, of which eight (17.4%) received target vessel revascularization, and four (8.7%) received target lesion revascularization. One patient (1.0%) died from sudden cardiac death. Conclusion: The clinical and angiographic follow-up results of this study involving relatively low- and intermediate- risk patients indicate that the use of the Genius TAXCOR I stents is effective and beneficial for the prevention of stent thrombosis and restenosis.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi Ortopedi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Uchida T, Bakhai A, Almonacid A, Shibata T, Cox B, Kuntz RE. A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis. Heart Vessels 2006;21:368-74.
  • 2. Drachman DE, Edelman ER, Seifert P, Groothuis AR, Bornstein DA, Kamath KR, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.
  • 3. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schröder S, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-76.
  • 4. Syed M, Lesch M. Coronary artery aneurysm: a review. Prog Cardiovasc Dis 1997;40:77-84.
  • 5. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
  • 6. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95.
  • 7. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
  • 8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
  • 9. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-31.
  • 10. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:156-75.
  • 11. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261-95.
  • 12. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/ AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/ SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306.
  • 13. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37:2215-39.
  • 14. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronarystent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
  • 15. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation 1999;100:1777-83.
  • 16. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999;34:1067-74.
  • 17. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007;50:1299-304.
  • 18. Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv 2009;74:665-73.
  • 19. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxeleluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60.
  • 20. Colombo A, Goldberg SL, Almagor Y, Maiello L, Finci L. A novel strategy for stent deployment in the treatment of acute or threatened closure complicating balloon coronary angioplasty. Use of short or standard (or both) single or multiple Palmaz-Schatz stents. J Am Coll Cardiol 1993; 22:1887-91.
  • 21. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
  • 22. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
  • 23. Sirnes PA, Golf S, Myreng Y, Mølstad P, Emanuelsson H, Albertsson P, et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996;28:1444-51.
  • 24. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
  • 25. Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 2003;107:517-20.
  • 26. Salam AM, Al Suwaidi J, Holmes DR Jr. Drug-eluting coronary stents. Curr Probl Cardiol 2006;31:8-119.
  • 27. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. One-year clinical results with the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
  • 28. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxeleluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
  • 29. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
  • 30. Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009;120:1498-504.
  • 31. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel- eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
APA KABAKÇI G, CANPOLAT U, ATEŞ A, YORGUN H, Sunman H, KAYA E, DURAL M, AYTEMIR K, Tokgozoglu L, Oto A (2011). Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. , 675 - 682.
Chicago KABAKÇI Giray,CANPOLAT Uğur,ATEŞ AHMET HAKAN,YORGUN HIKMET,Sunman Hamza,KAYA ERGUN BARIS,DURAL Muhammed,AYTEMIR KUDRET,Tokgozoglu Lale,Oto Ali Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. (2011): 675 - 682.
MLA KABAKÇI Giray,CANPOLAT Uğur,ATEŞ AHMET HAKAN,YORGUN HIKMET,Sunman Hamza,KAYA ERGUN BARIS,DURAL Muhammed,AYTEMIR KUDRET,Tokgozoglu Lale,Oto Ali Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. , 2011, ss.675 - 682.
AMA KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. . 2011; 675 - 682.
Vancouver KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. . 2011; 675 - 682.
IEEE KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A "Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi." , ss.675 - 682, 2011.
ISNAD KABAKÇI, Giray vd. "Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi". (2011), 675-682.
APA KABAKÇI G, CANPOLAT U, ATEŞ A, YORGUN H, Sunman H, KAYA E, DURAL M, AYTEMIR K, Tokgozoglu L, Oto A (2011). Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi, 39(8), 675 - 682.
Chicago KABAKÇI Giray,CANPOLAT Uğur,ATEŞ AHMET HAKAN,YORGUN HIKMET,Sunman Hamza,KAYA ERGUN BARIS,DURAL Muhammed,AYTEMIR KUDRET,Tokgozoglu Lale,Oto Ali Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi 39, no.8 (2011): 675 - 682.
MLA KABAKÇI Giray,CANPOLAT Uğur,ATEŞ AHMET HAKAN,YORGUN HIKMET,Sunman Hamza,KAYA ERGUN BARIS,DURAL Muhammed,AYTEMIR KUDRET,Tokgozoglu Lale,Oto Ali Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi, vol.39, no.8, 2011, ss.675 - 682.
AMA KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi. 2011; 39(8): 675 - 682.
Vancouver KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi. 2011; 39(8): 675 - 682.
IEEE KABAKÇI G,CANPOLAT U,ATEŞ A,YORGUN H,Sunman H,KAYA E,DURAL M,AYTEMIR K,Tokgozoglu L,Oto A "Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi." Türk Kardiyoloji Derneği Arşivi, 39, ss.675 - 682, 2011.
ISNAD KABAKÇI, Giray vd. "Paklitaksel salınımlı stent (Genius TAXCOR I) uygulamalarımızın izlem sonuçlarıyla birlikte geriye dönük değerlendirilmesi". Türk Kardiyoloji Derneği Arşivi 39/8 (2011), 675-682.